Uncontrolled blood pressure in patients with chronic kidney disease (CKD) can lead to serious adverse outcomes. To prevent the occurrence of cardiovascular events and CKD G5 requiring kidney replacement therapy, lowering blood pressure to optimal level is an important therapeutic intervention. Recently, there has been a paradigm shift in the management of BP largely owing to the Systolic Blood Pressure Intervention Trial (SPRINT), which showed clinical benefits in reducing adverse cardiovascular events by lowering systolic BP to 120 mmHg. This study also showed similar cardiovascular benefits in patients with CKD. Thus, the lower SBP target < 120 mmHg has gained wide recognition and has also been accepted by the Kidney Disease: Improving Global Outcomes (KDIGO) 2021 guideline. The goal of BP control in patients with CKD should encompass reduction in adverse cardiovascular events and mortality and attenuation of CKD progression. However, whether the intensive control of SBP targeting <120 mmHg is also effective in patients with CKD is still controversial. Notably, this lower target of SBP is associated with a higher risk of acute kidney injury and CKD. Unfortunately, there have been no randomized controlled trials on this issue solely involving patients with CKD, particularly those with advanced CKD. In this talk, I’ll discuss the optimal control of BP in patients with CKD in terms of reduction in death and cardiovascular events as well as attenuation of CKD progression based on current evidence-based literature.